Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $19.67 Consensus PT from Analysts
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) have earned an average recommendation of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year […]
Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) have earned an average recommendation of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year […]
